Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 374

1.
2.

Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure.

Gattis WA, O'Connor CM.

Am J Cardiol. 2004 May 6;93(9A):74B-6B.

PMID:
15144943
3.

Carvedilol use at discharge in patients hospitalized for heart failure is associated with improved survival: an analysis from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF).

Fonarow GC, Abraham WT, Albert NM, Stough WG, Gheorghiade M, Greenberg BH, O'Connor CM, Sun JL, Yancy C, Young JB; OPTIMIZE-HF Investigators and Coordinators.

Am Heart J. 2007 Jan;153(1):82.e1-11.

PMID:
17174643
4.
5.

Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF): rationale and design.

Fonarow GC, Abraham WT, Albert NM, Gattis WA, Gheorghiade M, Greenberg B, O'Connor CM, Yancy CW, Young J.

Am Heart J. 2004 Jul;148(1):43-51.

PMID:
15215791
6.

Demographics, clinical characteristics, and outcomes of patients hospitalized for decompensated heart failure: observations from the IMPACT-HF registry.

O'Connor CM, Stough WG, Gallup DS, Hasselblad V, Gheorghiade M.

J Card Fail. 2005 Apr;11(3):200-5.

PMID:
15812748
7.

Pre-discharge initiation of beta-blocker therapy in elderly patients hospitalized for acute decompensation of chronic heart failure: an effective strategy for the implementation of beta-blockade in heart failure.

Tarantini L, Cioffi G, Opasich C, Di Lenarda A, Pulignano G, Del Sindaco D, De Feo S, Stefenelli C, Russo P, Catania G.

Ital Heart J. 2004 Jun;5(6):441-9.

PMID:
15320569
8.

Influence of carvedilol on hospitalizations in heart failure: incidence, resource utilization and costs. U.S. Carvedilol Heart Failure Study Group.

Fowler MB, Vera-Llonch M, Oster G, Bristow MR, Cohn JN, Colucci WS, Gilbert EM, Lukas MA, Lacey MJ, Richner R, Young ST, Packer M.

J Am Coll Cardiol. 2001 May;37(6):1692-9.

9.

Safety and efficacy of carvedilol in severe heart failure. The U.S. Carvedilol Heart Failure Study Group.

Cohn JN, Fowler MB, Bristow MR, Colucci WS, Gilbert EM, Kinhal V, Krueger SK, Lejemtel T, Narahara KA, Packer M, Young ST, Holcslaw TL, Lukas MA.

J Card Fail. 1997 Sep;3(3):173-9.

PMID:
9330125
10.

Beta-blocker therapy for heart failure outside the clinical trial setting: findings of a community-based registry.

Franciosa JA, Massie BM, Lukas MA, Nelson JJ, Lottes S, Abraham WT, Fowler M, Gilbert EM, Greenberg B; COHERE Participant Physicians.

Am Heart J. 2004 Oct;148(4):718-26.

PMID:
15459606
11.

Impact of initiating carvedilol before angiotensin-converting enzyme inhibitor therapy on cardiac function in newly diagnosed heart failure.

Sliwa K, Norton GR, Kone N, Candy G, Kachope J, Woodiwiss AJ, Libhaber C, Sareli P, Essop R.

J Am Coll Cardiol. 2004 Nov 2;44(9):1825-30.

12.

Inpatient initiation of beta-blockade plus nurse management in vulnerable heart failure patients: a randomized study.

Krantz MJ, Havranek EP, Haynes DK, Smith I, Bucher-Bartelson B, Long CS.

J Card Fail. 2008 May;14(4):303-9. doi: 10.1016/j.cardfail.2007.12.008.

PMID:
18474343
13.

Early initiation of beta blockade in heart failure: issues and evidence.

Williams RE.

J Clin Hypertens (Greenwich). 2005 Sep;7(9):520-8; quiz 529-30. Review.

14.

Effects of carvedilol on left ventricular function and oxidative stress in infants and children with idiopathic dilated cardiomyopathy: a 12-month, two-center, open-label study.

Bajcetic M, Kokic Nikolic A, Djukic M, Kosutic J, Mitrovic J, Mijalkovic D, Jovanovic I, Simeunovic S, Spasic MB, Samardzic R.

Clin Ther. 2008 Apr;30(4):702-14.

PMID:
18498919
15.

Impact of a standardized titration protocol with carvedilol in heart failure: safety, tolerability, and efficacy-a report from the GESICA registry.

Nul D, Zambrano C, Diaz A, Ferrante D, Varini S, Soifer S, Grancelli H, Doval H; Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina.

Cardiovasc Drugs Ther. 2005 Mar;19(2):125-34.

PMID:
16025231
16.

Beta-blockers in heart failure. Do they improve the quality as well as the quantity of life?

Fowler MB.

Eur Heart J. 1998 Dec;19 Suppl P:P17-25. Review.

PMID:
9886708
17.

Comparative effectiveness of beta-adrenergic antagonists (atenolol, metoprolol tartrate, carvedilol) on the risk of rehospitalization in adults with heart failure.

Go AS, Yang J, Gurwitz JH, Hsu J, Lane K, Platt R.

Am J Cardiol. 2007 Aug 15;100(4):690-6. Epub 2007 Jun 26.

PMID:
17697830
18.

Carvedilol reduces aldosterone release in systolic heart failure.

Aggarwal A, Wong J, Campbell DJ.

Heart Lung Circ. 2006 Oct;15(5):306-9. Epub 2006 Aug 28.

PMID:
16935558
19.

Nonselective beta-adrenergic blockade with carvedilol does not hinder the benefits of exercise training in patients with congestive heart failure.

Demopoulos L, Yeh M, Gentilucci M, Testa M, Bijou R, Katz SD, Mancini D, Jones M, LeJemtel TH.

Circulation. 1997 Apr 1;95(7):1764-7.

20.

Rationale and design of the Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy for Heart Failure (IMPACT-HF) study.

Gheorghiade M, Gattis WA, Lukas MA, O'Connor CM; Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy for Heart Failure Investigators.

Am Heart J. 2003 Feb;145(2 Suppl):S60-1. No abstract available.

PMID:
12594455
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk